247 related articles for article (PubMed ID: 24975049)
1. Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma.
Wakamatsu T; Naka N; Sasagawa S; Tanaka T; Takenaka S; Araki N; Ueda T; Nishizawa Y; Yoshikawa H; Itoh K
Cancer Sci; 2014 Sep; 105(9):1124-34. PubMed ID: 24975049
[TBL] [Abstract][Full Text] [Related]
2. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
[TBL] [Abstract][Full Text] [Related]
3. SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.
Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Grünewald I; Huss S; Eßeling E; Mikesch JH; Hafner S; Simmet T; Wozniak A; Schöffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
Clin Cancer Res; 2019 Jun; 25(12):3718-3731. PubMed ID: 30814111
[TBL] [Abstract][Full Text] [Related]
4. SS18-SSX drives CREB activation in synovial sarcoma.
Cyra M; Schulte M; Berthold R; Heinst L; Jansen EP; Grünewald I; Elges S; Larsson O; Schliemann C; Steinestel K; Hafner S; Simmet T; Wardelmann E; Kailayangiri S; Rossig C; Isfort I; Trautmann M; Hartmann W
Cell Oncol (Dordr); 2022 Jun; 45(3):399-413. PubMed ID: 35556229
[TBL] [Abstract][Full Text] [Related]
5. Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein.
Yoneda Y; Ito S; Kunisada T; Morimoto Y; Kanzaki H; Yoshida A; Shimizu K; Ozaki T; Ouchida M
PLoS One; 2013; 8(10):e77564. PubMed ID: 24130893
[TBL] [Abstract][Full Text] [Related]
6. ATR Is a Therapeutic Target in Synovial Sarcoma.
Jones SE; Fleuren EDG; Frankum J; Konde A; Williamson CT; Krastev DB; Pemberton HN; Campbell J; Gulati A; Elliott R; Menon M; Selfe JL; Brough R; Pettitt SJ; Niedzwiedz W; van der Graaf WTA; Shipley J; Ashworth A; Lord CJ
Cancer Res; 2017 Dec; 77(24):7014-7026. PubMed ID: 29038346
[TBL] [Abstract][Full Text] [Related]
7. A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma.
Baranov E; McBride MJ; Bellizzi AM; Ligon AH; Fletcher CDM; Kadoch C; Hornick JL
Am J Surg Pathol; 2020 Jul; 44(7):922-933. PubMed ID: 32141887
[TBL] [Abstract][Full Text] [Related]
8. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics.
Su L; Sampaio AV; Jones KB; Pacheco M; Goytain A; Lin S; Poulin N; Yi L; Rossi FM; Kast J; Capecchi MR; Underhill TM; Nielsen TO
Cancer Cell; 2012 Mar; 21(3):333-47. PubMed ID: 22439931
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
Lubieniecka JM; de Bruijn DR; Su L; van Dijk AH; Subramanian S; van de Rijn M; Poulin N; van Kessel AG; Nielsen TO
Cancer Res; 2008 Jun; 68(11):4303-10. PubMed ID: 18519690
[TBL] [Abstract][Full Text] [Related]
10. Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma.
Raquib AR; Hofvander J; Ta M; Nielsen TO
Appl Immunohistochem Mol Morphol; 2022 Sep; 30(8):531-539. PubMed ID: 35880992
[TBL] [Abstract][Full Text] [Related]
11. Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth.
Törnkvist M; Natalishvili N; Xie Y; Girnita A; D'Arcy P; Brodin B; Axelson M; Girnita L
Biochem Biophys Res Commun; 2008 Apr; 368(3):793-800. PubMed ID: 18267106
[TBL] [Abstract][Full Text] [Related]
12. Utility of Immunohistochemistry With Antibodies to SS18-SSX Chimeric Proteins and C-Terminus of SSX Protein for Synovial Sarcoma Differential Diagnosis.
Lasota J; Chłopek M; Kaczorowski M; Natálie K; Ryś J; Kopczyński J; Sulaieva O; Michal M; Kruczak A; Harazin-Lechowska A; Szczepaniak M; Koshyk O; Hałoń A; Czapiewski P; Abdullaev Z; Kowalik A; Aldape KD; Michal M; Miettinen M
Am J Surg Pathol; 2024 Jan; 48(1):97-105. PubMed ID: 37899499
[TBL] [Abstract][Full Text] [Related]
13. When used together SS18-SSX fusion-specific and SSX C-terminus immunohistochemistry are highly specific and sensitive for the diagnosis of synovial sarcoma and can replace FISH or molecular testing in most cases.
Zaborowski M; Vargas AC; Pulvers J; Clarkson A; de Guzman D; Sioson L; Maclean F; Chou A; Gill AJ
Histopathology; 2020 Oct; 77(4):588-600. PubMed ID: 32559341
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of SS18-SSX1 expression in synovial sarcoma by small interfering RNA enhances the focal adhesion pathway and inhibits anchorage-independent growth in vitro and tumor growth in vivo.
Takenaka S; Naka N; Araki N; Hashimoto N; Ueda T; Yoshioka K; Yoshikawa H; Itoh K
Int J Oncol; 2010 Apr; 36(4):823-31. PubMed ID: 20198325
[TBL] [Abstract][Full Text] [Related]
15. Proteomic signatures corresponding to the SS18/SSX fusion gene in synovial sarcoma.
Ishii M; Suehara Y; Sano K; Kohsaka S; Hayashi T; Kazuno S; Akaike K; Mukaihara K; Kim Y; Okubo T; Takamochi K; Takahashi F; Kaneko K; Saito T
Oncotarget; 2018 Dec; 9(101):37509-37519. PubMed ID: 30680066
[TBL] [Abstract][Full Text] [Related]
16. SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1.
Minami Y; Kohsaka S; Tsuda M; Yachi K; Hatori N; Tanino M; Kimura T; Nishihara H; Minami A; Iwasaki N; Tanaka S
Cancer Sci; 2014 Sep; 105(9):1152-9. PubMed ID: 24989082
[TBL] [Abstract][Full Text] [Related]
17. A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18-SSX Induces Canonical BAF Destruction.
Li J; Mulvihill TS; Li L; Barrott JJ; Nelson ML; Wagner L; Lock IC; Pozner A; Lambert SL; Ozenberger BB; Ward MB; Grossmann AH; Liu T; Banito A; Cairns BR; Jones KB
Cancer Discov; 2021 Oct; 11(10):2620-2637. PubMed ID: 34078620
[TBL] [Abstract][Full Text] [Related]
18. Identification of SHCBP1 as a novel downstream target gene of SS18-SSX1 and its functional analysis in progression of synovial sarcoma.
Peng C; Zhao H; Chen W; Song Y; Wang X; Li J; Qiao Y; Wu D; Ma S; Wang X; Gao C
Oncotarget; 2016 Oct; 7(41):66822-66834. PubMed ID: 27572315
[TBL] [Abstract][Full Text] [Related]
19. Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma.
Carmody Soni EE; Schlottman S; Erkizan HV; Uren A; Toretsky JA
Clin Orthop Relat Res; 2014 Mar; 472(3):874-82. PubMed ID: 23716114
[TBL] [Abstract][Full Text] [Related]
20. Immunoreactivity of a Monoclonal Antibody to SS18-SSX Fusion Gene Product in Formalin-fixed Paraffin-embedded Synovial Sarcoma Tissue Section.
Saigo C; Kito Y; Takeuchi T
Appl Immunohistochem Mol Morphol; 2018 Mar; 26(3):206-211. PubMed ID: 27362474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
